Amarin reported $26.05M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amarin USD 26.05M 1.41M Dec/2025
AstraZeneca USD 2.52B 2.73B Jun/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Halozyme Therapeutics USD 108.68M 67K Jun/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 39.4M 25.6M Jun/2026
Novartis USD 3.71B 251M Jun/2026